SHORT REPORT
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer
Division of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
Correspondence to:
Dr M Clemons, Medical Oncology, Princess Margaret Hospital (5-205), 610 University Avenue, Toronto, ON M5G 2M9, Canada; mark.clemons{at}uhn.on.ca
Background: Recent data have shown a fall in vascular endothelial growth factor (VEGF) concentrations after bisphosphonate (BP) treatment in BP-naïve patients. It has therefore been proposed that BPs may have in vivo anti-VEGF effects.
Aims: To explore whether VEGF concentrations change after administration of a more potent BP in patients receiving long-term BP treatment.
Methods: 31 patients with breast cancer who had progressive metastatic bone disease despite treatment with early-generation BPs were switched to zoledronic acid. Serum VEGF concentrations were measured at baseline, and weeks 1, 2, 3, 4, 8 and 12.
Results: VEGF concentration per platelet count did not change significantly at any time during the 12 weeks after treatment with zoledronic acid.
Conclusions: Switching to zoledronic acid did not suppress circulating serum VEGF concentrations in BP-pretreated patients. Novel approaches to assess the effect of BPs on the bone milieu may provide further insight into the possible antiangiogenic properties of BPs.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
